News

An alternative method of recycling mitochondria — the cell’s powerhouses — that involves pushing damaged mitochondria out of cells, seems to play a role in Parkinson’s disease, according to a recent study. Researchers have found evidence in cellular and animal models of disease that this process is enhanced in the…

Older age, male sex, and a family history of Parkinson’s disease appear to associate with a higher risk of developing Parkinson’s later in life, according to an Italian study. The research also suggested that dietary choices and work history influenced the disease’s development, with those who consumed meat on…

Higher levels of neurofilament light chain (NfL) — a biomarker of nerve cell damage — inside small vesicles in the blood associate with more severe motor symptoms, particularly slow movement and rigidity, in people with Parkinson’s disease, a small study suggests. However, no significant changes in NfL levels inside these…

Throughout 2020, Parkinson’s News Today brought you daily coverage of important discoveries, treatment advancements, preclinical and clinical studies, and other relevant events related to Parkinson’s disease. We are looking forward to bringing more news this year to those with Parkinson’s, their caregivers, and loved ones. Here we present our 10…

4D Pharma, a biotechnology company focused on gut microbiota-based therapies, has joined the Parkinson’s Progression Markers Initiative (PPMI), an observational study helping to identify biomarkers of Parkinson’s progression and new ways of treating the disease. …

Patients with Parkinson’s disease are two times more likely to commit suicide than people from the general population, according to data from a Taiwanese population-based study. Importantly, this increased risk of self-inflicted death was found to be independent of socioeconomic status, dementia, and the presence of other mental disorders,…

Pharmather has filed a request to meet with the U.S. Food and Drug Administration (FDA) to determine next best steps in the clinical development of ketamine to treat the levodopa-induced dyskinesia associated with Parkinson’s disease. The filing is in preparation for a proposed Phase 2 clinical study of ketamine,…

Eli Lilly has announced an agreement to acquire biotechnology company Prevail Therapeutics. Following the deal, Lilly plans to create a gene therapy program for people with neurodegenerative diseases, including Parkinson’s. “The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly,…

The Michael J. Fox Foundation (MJFF) has awarded a grant to Sengenics for work in identifying new autoantibody signatures in people at high risk of Parkinson’s disease, and to investigate these proteins’ role in the disease’s course. “We are delighted to have been awarded this prestigious Michael J. Fox Foundation research…

Most people who undergo genetic testing and counseling related to Parkinson’s disease are satisfied with their experience and feel no substantially adverse psychological effects, a study reported. However, its findings also indicated that people with diagnosed Parkinson’s, or in whom Parkinson’s-linked mutations are identified, are more likely to be…